Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Abstract Background We explored whether serum cytokines could be used as biomarkers for optimal use of tumor necrosis factor inhibitors (TNF-i) and interleukin (IL)-17 inhibitors (IL-17-i) in patients with psoriatic arthritis (PsA). Methods In cohort 1 (47 patients treated with IL-17-i [n=23] or TNF...

Full description

Bibliographic Details
Main Authors: Ippei Miyagawa, Shingo Nakayamada, Masanobu Ueno, Yusuke Miyazaki, Shigeru Iwata, Satoshi Kubo, Koshiro Sonomoto, Junpei Anan, Naoaki Ohkubo, Yoshino Inoue, Yoshiya Tanaka
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Arthritis Research & Therapy
Subjects:
Psoriatic arthritis
Precision medicine
Interleukin-22
Tumor necrosis factor inhibitors
Interleukin-17 inhibitors
Online Access:https://doi.org/10.1186/s13075-022-02771-4

Internet

https://doi.org/10.1186/s13075-022-02771-4

Similar Items